Tag: reprints


House Approves 21st Century Cures Act, Bill Now Heads to the Senate

July 10, 2015 — The House of Representatives today passed H.R. 6, also known as the 21st Century Cures Act, by an overwhelming majority of 344-77. The legislation, which includes three provisions that are important to healthcare marketers, now heads to the Senate. The bill’s authors, House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), […]

Read more

CMS: Textbooks and Reprints Do Not Fall Under Sunshine Act Statutory Exclusion

Jan. 10, 2014 – According to a recent article in Policy and Medicine, a letter from Centers for Medicare & Medicaid Services (CMS) Administrator Marilyn Tavenner to several members of Congress states that although CMS agrees that textbooks and medical reprints are educational, “‘we do not believe these materials fall within the statutory exclusion’” of […]

Read more

House Members Speak Out Against Inclusion of Textbooks, Reprints in Sunshine Act Reporting

Nov. 26, 2013 – On Nov. 22, 23 members of the U.S. House of Representatives sent a letter to the Centers for Medicare & Medicaid Services (CMS) to voice their disagreement with the Department of Health and Human Services (HHS) decision to include textbooks and scientifically peer-reviewed medical journals as “transfers of value” reportable under […]

Read more

Physician Organizations, Medical Societies Implore HHS to Reverse Policy on Reprints and Textbooks

Oct. 28, 2013 – On Monday, 33 physician organizations and 41 national and state medical societies sent a letter to Department of Health and Human Services (HHS) Secretary Kathleen Sebelius to express their “serious concerns” about Sunshine Act regulations that consider journal reprints and medical textbooks to be “transfers of value” which are reportable under […]

Read more

J&J Settlement Restricts Marketing Distribution of Journal Article Reprints

Sept. 10, 2012 – A recent settlement between Johnson & Johnson/Janssen and multiple states to resolve claims that the company promoted unapproved uses for its antipsychotic drugs Risperdal and Invega is significant not only because J&J will pay $181 million but also because, among several provisions, the settlement restricts J&J’s ability to distribute reprints of […]

Read more